United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 1,234 shares of the company’s stock in a transaction on Thursday, June 22nd. The stock was sold at an average price of $132.32, for a total transaction of $163,282.88. Following the transaction, the chief executive officer now directly owns 1,374 shares in the company, valued at $181,807.68. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Shares of United Therapeutics Corporation (UTHR) traded down 0.25% during mid-day trading on Friday, reaching $131.37. The company had a trading volume of 63,612 shares. United Therapeutics Corporation has a 12-month low of $97.52 and a 12-month high of $169.89. The stock has a market capitalization of $5.92 billion, a P/E ratio of 9.22 and a beta of 1.56. The firm’s 50 day moving average is $124.68 and its 200-day moving average is $138.61.

United Therapeutics Corporation (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, April 26th. The biotechnology company reported $3.89 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $3.12 by $0.77. United Therapeutics Corporation had a return on equity of 34.74% and a net margin of 41.04%. The company had revenue of $370.50 million for the quarter, compared to analyst estimates of $399.59 million. During the same quarter last year, the company posted $3.02 EPS. The company’s revenue for the quarter was up .4% compared to the same quarter last year. On average, analysts expect that United Therapeutics Corporation will post $14.42 earnings per share for the current fiscal year.

Insider Buying and Selling by Quarter for United Therapeutics Corporation (NASDAQ:UTHR)

COPYRIGHT VIOLATION WARNING: This news story was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this news story can be accessed at https://www.thecerbatgem.com/2017/06/23/insider-selling-united-therapeutics-corporation-uthr-ceo-sells-1234-shares-of-stock.html.

A number of research firms have issued reports on UTHR. Oppenheimer Holdings, Inc. restated a “buy” rating on shares of United Therapeutics Corporation in a report on Monday, April 3rd. ValuEngine downgraded shares of United Therapeutics Corporation from a “strong-buy” rating to a “buy” rating in a research report on Friday, June 2nd. Zacks Investment Research downgraded shares of United Therapeutics Corporation from a “buy” rating to a “hold” rating in a research report on Monday, February 27th. J P Morgan Chase & Co set a $125.00 price target on shares of United Therapeutics Corporation and gave the stock a “hold” rating in a research report on Tuesday, April 11th. Finally, HC Wainwright reissued a “hold” rating and set a $95.00 price target on shares of United Therapeutics Corporation in a research report on Monday, April 17th. Three investment analysts have rated the stock with a sell rating, nine have issued a hold rating and three have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $137.09.

Large investors have recently added to or reduced their stakes in the stock. Skandinaviska Enskilda Banken AB publ increased its position in shares of United Therapeutics Corporation by 1.1% in the first quarter. Skandinaviska Enskilda Banken AB publ now owns 661,723 shares of the biotechnology company’s stock valued at $89,584,000 after buying an additional 6,900 shares during the last quarter. Public Employees Retirement System of Ohio increased its position in shares of United Therapeutics Corporation by 0.7% in the first quarter. Public Employees Retirement System of Ohio now owns 20,886 shares of the biotechnology company’s stock worth $2,828,000 after buying an additional 155 shares in the last quarter. Achmea Investment Management B.V. acquired a new position in shares of United Therapeutics Corporation during the first quarter worth about $2,297,000. Janus Capital Management LLC increased its position in shares of United Therapeutics Corporation by 122.1% in the first quarter. Janus Capital Management LLC now owns 14,305 shares of the biotechnology company’s stock worth $1,936,000 after buying an additional 7,863 shares in the last quarter. Finally, HighTower Advisors LLC increased its position in shares of United Therapeutics Corporation by 2.1% in the first quarter. HighTower Advisors LLC now owns 36,179 shares of the biotechnology company’s stock worth $4,869,000 after buying an additional 743 shares in the last quarter.

About United Therapeutics Corporation

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Receive News & Stock Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related stocks with our FREE daily email newsletter.